Literature DB >> 9427057

Overwhelming postsplenectomy infection with vaccine-type Streptococcus pneumoniae in a 12-year-old girl despite vaccination and antibiotic prophylaxis.

J Klinge1, G Hammersen, J Scharf, R Lütticken, R R Reinert.   

Abstract

This report describes a 12-year-old girl who developed vaccine-type pneumococcal septicemia (type 4, Danish nomenclature) 2 years after splenectomy for recurrent idiopathic thrombocytopenia despite vaccination with the 23-valent vaccine 4 weeks before surgery and antibiotic prophylaxis with penicillin V. The disease presented as high fever with shivering and vomiting followed by disseminated petechiae and a deteriorated general condition. Initial laboratory studies showed severe sepsis with leucocytopenia and thrombocytopenia, a markedly elevated CRP, and disseminated intravascular coagulation. Despite antibiotic treatment, which was initiated with clindamycin, cefotaxime and trimethoprim/sulfamethoxazole and was switched to cefotaxime and penicillin after the result of the blood culture had been obtained, the patient had to be ventilated, and hemofiltration became necessary because of acute renal insufficiency. Furthermore, she required amputation of all her toes because of severe necrosis. No type-specific pneumococcal antibody titers were detected during and after infection. It remains unclear whether the susceptibility to Streptococcus pneumoniae was due to primary failure of antibody production or a decline in antibody levels after vaccination. Patients and/or their relatives should be informed that neither vaccination nor continuous antibiotic prophylaxis can guarantee full protection against infection with S. pneumoniae in patients after splenectomy.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9427057     DOI: 10.1007/bf01740820

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  18 in total

1.  The hazard of infection following splenectomy in children.

Authors:  W D Erickson; E O Burgert; H B Lynn
Journal:  Am J Dis Child       Date:  1968-07

2.  Fatal post-splenectomy sepsis despite prophylaxis with penicillin and pneumococcal vaccine.

Authors:  D I Evans
Journal:  Lancet       Date:  1984-05-19       Impact factor: 79.321

3.  Impaired immune response of splenectomised patients to polyvalent pneumococcal vaccine.

Authors:  S W Hosea; C G Burch; E J Brown; R A Berg; M M Frank
Journal:  Lancet       Date:  1981-04-11       Impact factor: 79.321

4.  Chemoprophylaxis in asplenic adolescents and young adults.

Authors:  G R Buchanan
Journal:  Pediatr Infect Dis J       Date:  1993-10       Impact factor: 2.129

5.  Postsplenectomy infections in Danish children splenectomized 1969-1978.

Authors:  F K Pedersen
Journal:  Acta Paediatr Scand       Date:  1983-07

6.  Pneumococcal vaccine in children and young adults with chronic renal disease.

Authors:  A Fuchshuber; O Kühnemund; B Keuth; R Lütticken; D Michalk; U Querfeld
Journal:  Nephrol Dial Transplant       Date:  1996-03       Impact factor: 5.992

Review 7.  Pneumococcal polysaccharide vaccines: indications, efficacy and recommendations.

Authors:  G A Bruyn; R van Furth
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-11       Impact factor: 3.267

8.  [Risk of infection and surgical consequences of splenic loss in childhood].

Authors:  H G Roth
Journal:  Langenbecks Arch Chir       Date:  1986

9.  Serum antibody responses to vaccination with 23-valent pneumococcal vaccine in splenectomized patients.

Authors:  R R Reinert; A Kaufhold; O Kühnemund; R Lütticken
Journal:  Zentralbl Bakteriol       Date:  1994-11

10.  [Post-splenectomy infections and Pneumococcus vaccination in paediatric surgery (author's transl)].

Authors:  B H Belohradsky; S Däumling; R Roos; A M Holschneider; C Griscelli
Journal:  Z Kinderchir       Date:  1982-04
View more
  1 in total

1.  Overwhelming infection in asplenic patients: current best practice preventive measures are not being followed.

Authors:  D J Waghorn
Journal:  J Clin Pathol       Date:  2001-03       Impact factor: 3.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.